Compare HTLD & ANL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HTLD | ANL |
|---|---|---|
| Founded | 1978 | 2004 |
| Country | United States | Singapore |
| Employees | N/A | N/A |
| Industry | Trucking Freight/Courier Services | |
| Sector | Industrials | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 998.8M |
| IPO Year | 1995 | 2022 |
| Metric | HTLD | ANL |
|---|---|---|
| Price | $11.16 | $15.99 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 6 | 7 |
| Target Price | $13.20 | ★ $29.50 |
| AVG Volume (30 Days) | ★ 670.2K | 181.7K |
| Earning Date | 10-30-2026 | 08-14-2026 |
| Dividend Yield | ★ 0.70% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.07 | N/A |
| Revenue | ★ $805,709,000.00 | N/A |
| Revenue This Year | N/A | $243.83 |
| Revenue Next Year | $8.43 | N/A |
| P/E Ratio | $162.14 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $7.00 | $0.88 |
| 52 Week High | $16.64 | $17.25 |
| Indicator | HTLD | ANL |
|---|---|---|
| Relative Strength Index (RSI) | 35.57 | 57.29 |
| Support Level | $10.67 | $14.70 |
| Resistance Level | $11.48 | $17.10 |
| Average True Range (ATR) | 0.34 | 1.18 |
| MACD | -0.01 | -0.10 |
| Stochastic Oscillator | 11.83 | 70.03 |
Heartland Express Inc, along with its subsidiaries, operates as a short, medium, and long-haul truckload carrier and transportation services provider. It mainly provides nationwide asset-based dry van truckload service for shippers across the United States, along with cross-border freight and other transportation services offered through third-party partnerships in Mexico. The group operates under the brand names of Heartland Express, Millis Transfer, Smith Transport, and CFI (for services within Mexico).
Adlai Nortye Ltd is a clinical-stage company at the forefront of discovering and developing cancer therapies. The company is building a robust pipeline of drug candidates focused on two key areas where it believes it can make a difference RAS-targeting therapies: its is tackling RAS-driven cancers with AN9025, an oral pan-RAS(ON) inhibitor, and AN4035, a CEACAM5-targeting ADC delivering a potent pan-RAS(ON) inhibitor directly to tumors; Next-generation cancer immunotherapies: its candidates, AN8025 (a tri-functional fusion protein of alphaPD-L1 x CD86 variant x LAG3 variant), a T-cell and antigen-presenting cell modulator, and AN4005 (a first-in-class oral small-molecule PD-L1 inhibitor), are designed to activate cancer immunity in novel ways.